Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61801
Type: Artigo de Periódico
Title: Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
Authors: Carla Boquimpani
Fernanda Salles Seguro
Gustavo Henrique Romani Magalhães
Ingrid Luise Soares Pinto
Israel Bendit
Jaisson André Pagnoncelli Bortolini
Katia Borgia Barbosa Pagnano
Renato Centrone
Vaneuza Funke
Abstract: Introduction Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil, for example, molecular tests (BCR::ABL1) are not broadly available, making it difficult to monitor the patients adequately. Objective In this sense, providing TFR recommendations for Brazilian physicians are therefore necessary. These recommendations include the main criteria checklist to start the TKIs treatment discontinuing process in patients diagnosed with CML and the population-eligible characteristics for treatment discontinuation. Method Age, risk score at diagnosis, TKI treatment duration, BCR::ABL1 transcripts type, depth of the molecular response for treatment discontinuation, treatment adherence, patient monitoring and withdrawal syndrome are essential factors to consider in TFR. After TKI discontinuation, BCR::ABL1 transcripts monitoring should be more frequent. When a major molecular response loss is observed during the monitoring of a patient in TFR, the TKI treatment should be resumed.
Subject: Neoplasias
Guia de Prática Clínica
Terapêutica
language: eng
metadata.dc.publisher.country: Brasil
Publisher: Universidade Federal de Minas Gerais
Publisher Initials: UFMG
metadata.dc.publisher.department: MEDICINA - FACULDADE DE MEDICINA
Rights: Acesso Aberto
metadata.dc.identifier.doi: https://doi.org/10.1016/j.htct.2022.04.002
URI: http://hdl.handle.net/1843/61801
Issue Date: 2022
metadata.dc.url.externa: https://www.sciencedirect.com/science/article/pii/S2531137922000505?via%3Dihub
metadata.dc.relation.ispartof: Hematology, Transfusion and Cell Therapy
Appears in Collections:Artigo de Periódico



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.